Kestra Medical Technologies (NASDAQ:KMTS) Posts Earnings Results, Misses Expectations By $0.61 EPS

Kestra Medical Technologies (NASDAQ:KMTS) issued its earnings results on Monday. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.61), RTT News reports.

Kestra Medical Technologies Stock Down 1.9 %

KMTS stock traded down $0.45 on Monday, reaching $23.83. 131,018 shares of the company traded hands, compared to its average volume of 272,564. Kestra Medical Technologies has a one year low of $20.00 and a one year high of $26.06.

Wall Street Analyst Weigh In

KMTS has been the subject of a number of analyst reports. Wolfe Research began coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set an “outperform” rating and a $29.00 target price for the company. Piper Sandler initiated coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They issued an “overweight” rating and a $27.00 price target for the company. Wells Fargo & Company assumed coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They issued an “overweight” rating and a $28.00 price objective for the company. Bank of America began coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They set a “buy” rating and a $30.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued a “buy” rating and a $28.00 target price for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.